News & Blog
During the COVID-19 pandemic, low-barrier care provided vital services and treatment to people with opioid use disorder. In this recap, fellow speakers share new approaches that can continue the momentum and reduce the toll of opioid overdose deaths.
Coming to New York City was an easy decision for Harkness Fellow Ane-Kristine Finbraten. The city has one of the most robust hepatitis C elimination efforts to learn from.
The development of direct-acting antivirals transformed hepatitis C virus (HCV) therapy, allowing patients to experience fewer side effects and non-specialist providers to prescribe HCV treatment with more ease. Despite these advances, existing social and structural barriers, such as stigma and accessibility of medical care, restrict access to effective HCV treatment for people who use drugs who are co-infected with HIV and HCV.
This article is cross-posted at the University of Pennsylvania Leonard Davis Institute. Penn aluma and former Louisiana Secretary of Health Rebekah Gee detailed some of the strategies her team used to get a Medications for Opioid Use Disorder law passed in one of the country’s most conservative states. If you want to reform state laws […]
In November 2020, Oregonians voted to pass Measure 110, a ballot initiative that decriminalizes the possession of small amounts of all drugs and increases access to low-barrier substance use disorder treatment and harm reduction services. Led by the Drug Policy Alliance, the ballot measure is a historic step forward to address drug-related arrests that disproportionally […]
The evidence suggests that low-threshold approaches can increase access to treatment, with outcomes comparable to high-barrier, standard care.